

# **Role of Bone Morphogenetic Protein-2 in Primary Osteoarthritis**

*Thesis*

*Submitted for partial fulfillment of Master Degree  
in Physical medicine, Rheumatology and Rehabilitation*

*By*

**Miriam Raafat Sadek Bekhit**

M.B., B.Ch.

Faculty of Medicine- Ain Shams University

*Under Supervision of*

**Prof. Doc. Nadia Abdel Salam El Kadery**

Professor of Physical Medicine, Rheumatology and Rehabilitation  
Faculty of Medicine, Ain Shams University

**Prof. Doc. Henaz Farouk Khaled**

Professor of Physical Medicine, Rheumatology and Rehabilitation  
Faculty of Medicine, Ain Shams University

**Assist. Prof. Doc. Abeer Ahmed Kadry Elzoheiry**

Assistant Professor of Physical Medicine, Rheumatology and  
Rehabilitation Faculty of Medicine, Ain Shams University

**Faculty of Medicine  
Ain Shams University**

**2014**

---





## Acknowledgement

First and foremost I would like to express my sincere gratitude to *Prof. Dr. Madia Abdel Salam EL Kadery*, Professor of Physical Medicine, Rheumatology and Rehabilitation, Faculty of Medicine, Ain Shams University, for her continuous support, patience, motivation and immense knowledge.

My sincere thanks also goes to *Prof. Dr. Henaz Farouk Khaled*, Professor of Physical Medicine, Rheumatology and Rehabilitation, Faculty of Medicine, Ain Shams University, for her excellent guidance, caring, valuable advice and insight throughout my work.

I owe my deepest appreciation to *Assist Prof. Dr. Abeer Ahmed Kadry Elzoheiry*, Assistant Professor of Physical Medicine, Rheumatology and Rehabilitation, Faculty of Medicine, Ain Shams University, for her kind assistance, support, encouragement and providing coherent answers to my questions.

Last but not the least; I would like to thank my *Family* for supporting and encouraging me always with their best wishes.

---

# List of Contents

<i>Subject</i>	<i>Page No.</i>
List of Abbreviations .....	i
List of Tables .....	v
List of Figures.....	vi
Introduction.....	1
Aim of the Work.....	6
Review of Literature	
- Pathogenesis.....	7
- Bone Morphogenetic Proteins .....	19
- Bone Morphogenetic Proteins in Joint Diseases.....	39
- Assessment of Osteoarthritis Severity .....	49
Patients and Methods.....	55
Results.....	68
Discussion.....	84
Summary and Conclusion .....	94
Recommendations.....	99
References.....	100
Arabic Summary .....	—

## List of Abbreviations

Abbrev.	Meaning
<b>ABC</b>	: Avidin-Biotin-Peroxidase Complex
<b>ACR</b>	: American college of rheumatology
<b>ActR</b>	: Activin receptor
<b>ADAMTS</b>	: A disintegrin and metalloproteinase with thrombospondin motifs
<b>ALK</b>	: Activin receptor–like kinase
<b>ALP</b>	: Alkaline phosphatase
<b>ALT</b>	: Alanine transaminase
<b>Ang</b>	: Angiopoietin
<b>AST</b>	: Aspartate Aminotransferase
<b>AUC</b>	: Area under the curve
<b>BMI</b>	: Body mass index
<b>BMPR</b>	: Bone morphogenetic protein receptor
<b>BMPs</b>	: Bone morphogenetic proteins
<b>BUN</b>	: Blood urea nitrogen
<b>C Smad</b>	: Common partner Smads
<b>CBC</b>	: Complete blood count
<b>Cbfa1</b>	: Corebinding factor-1
<b>CDMP</b>	: Cartilage-derived morphogenetic protein
<b>COMP</b>	: Cartilage oligomeric matrix protein
<b>CRP</b>	: C-reactive protein
<b>CSF1</b>	: Colony-syimulating factor-1
<b>CT</b>	: Computed tomography
<b>DDR2</b>	: Discoidin domain receptor 2
<b>DKK</b>	: Dickkopf factors
<b>DM</b>	: Diabetes Mellitus
<b>ECM</b>	: Extracellular matrix
<b>EDTA</b>	: Ethylenediaminetetraacetic acid
<b>EGF</b>	: Epidermal growth factor

## List of Abbreviations *(Cont...)*

Abbrev.	Meaning
<b>ELISA</b>	: Enzyme-linked immunosorbent assay
<b>ER</b>	: Endoplasmic reticulum
<b>ERK</b>	: Extracellular signal-regulated kinase
<b>ESR</b>	: Erythrocyte sedimentation rate
<b>EULAR</b>	: European League Against Rheumatism
<b>FBS</b>	: Fasting blood sugar
<b>FGF</b>	: Fibroblast growth factor
<b>FKBP12</b>	: FK-binding protein 12
<b>FN</b>	: False negative
<b>FP</b>	: False positive
<b>FZD</b>	: Frizzled receptors
<b>GDF</b>	: Growth differentiation factor
<b>GDNF</b>	: Glial cell line derived neurotrophic factor
<b>GPI</b>	: Glycosylphosphatidylinositol
<b>GRO <math>\alpha</math></b>	: Growth regulated oncogene $\alpha$
<b>GS</b>	: Glycine-Serine
<b>GTPase</b>	: Guanosinetriphosphatase
<b>Hg</b>	: Haemoglobin
<b>HGF</b>	: Hepatocyte growth factor
<b>HIF</b>	: Hypoxic inducible factor
<b>HISS</b>	: Hepatic insulin-sensitizing substance
<b>HMG</b>	: High mobility group
<b>HS</b>	: Highly significant
<b>IGF</b>	: Insulin-like growth factor
<b>IL</b>	: Interleukin
<b>I-Smad</b>	: Inhibitory Smad
<b>JNK</b>	: Jun N-terminal kinase
<b>K-L</b>	: Kellgren and Lawrence scoring system
<b>KOOS</b>	: Knee injury and osteoarthritis outcome score

## List of Abbreviations *(Cont...)*

Abbrev.	Meaning
<b>LRP5/6</b>	: Lipoprotein receptor-related protein 5/6
<b>MAP</b>	: Mitogen activated protein
<b>MCP1</b>	: Monocyte chemotactic protein 1
<b>M-CSF</b>	: Macrophage colony-stimulating factor
<b>MIP</b>	: Macrophage inflammatory protein
<b>MISIR</b>	: Mullerian inhibiting substance receptor
<b>MMPs</b>	: Matrix metalloproteinases
<b>MRI</b>	: Magnetic resonance imaging
<b>MSC</b>	: Mesenchymal stem cells
<b>NGF</b>	: Nerve growth factor
<b>NO</b>	: Nitric oxide
<b>NPRS</b>	: Numeric pain rating scale
<b>NS</b>	: Non significant
<b>OA</b>	: Osteoarthritis
<b>OP-1</b>	: Osteogenic protein-1
<b>OPG</b>	: Osteoprotegrin
<b>PDGF</b>	: Platelet-derived growth factor
<b>PGs</b>	: Prostaglandins
<b>PLT</b>	: Platelets
<b>PTH</b>	: Parathyroid hormone
<b>R -Smad</b>	: Regulated Smad
<b>RA</b>	: Rheumatoid arthritis
<b>RANK-L</b>	: Receptor activator of NF-k B ligand
<b>RANTES</b>	: Regulated and normal T-cell expressed and secreted
<b>RF</b>	: Rheumatoid factor
<b>RGM</b>	: Repulsive guidance molecule
<b>rhBMPs</b>	: Recombinant human Bone morphogenetic protein
<b>ROC</b>	: Receiver operating characteristic
<b>R-Smad</b>	: Regulated Smad

## List of Abbreviations *(Cont...)*

Abbrev.	Meaning
<b>RUNX2</b>	: Runt-related transcription factor 2
<b>S</b>	: Significant
<b>SD</b>	: Standard deviation
<b>sFRPs</b>	: Secreted frizzled related proteins
<b>SGOT</b>	: Serum glutamic oxaloacetic transaminase
<b>SGPT</b>	: Serum glutamic-pyruvic transaminase
<b>SLE</b>	: Systemic lupus erythematosus
<b>SMAD</b>	: Small mother against decapentaplegic
<b>SOX-9</b>	: SRY-related high-mobility-group box transranscription factor 9
<b>SpA</b>	: Spondyloarthropathy
<b>SPSS</b>	: Statistical package for Social Science
<b>TGF-<math>\beta</math></b>	: Transforming growth factor $\beta$
<b>TLR</b>	: Toll-like receptor
<b>TMB</b>	: Tetramethylbenzidine
<b>TN</b>	: True negative
<b>TNF</b>	: Tumor necrosis factor
<b>TP</b>	: True positive
<b>Tsg</b>	: Twisted gastrulation
<b>USAG-1</b>	: Uterine sensitization-associated gene-1
<b>VEGF</b>	: vascular endothelial growth factor
<b>WBC</b>	: White blood cells
<b>Wifs</b>	: Wnt inhibitory factors
<b>Wnt</b>	: Wingless proteins
<b>WOMAC</b>	: Western Ontario and McMaster university osteoarthritis index



## List of Tables

<i>Table No.</i>	<i>Title</i>	<i>Page No.</i>
<b>Table (1):</b>	Known BMPs. BMPs, their expression, chromosome, known functions .....	21
<b>Table (2):</b>	The Western Ontario and McMaster University Osteoarthritis Index (WOMAC) .....	60
<b>Table (3):</b>	Sex groups Cross Tabulation.....	68
<b>Table (4):</b>	Descriptive parameters of the patients .....	69
<b>Table (5):</b>	Descriptive parameters of the controls .....	70
<b>Table (6):</b>	Frequencies of clinical manifestations among studied patients .....	71
<b>Table (7):</b>	Comparison between patients and controls .....	72
<b>Table (8):</b>	Radiological classification of patients according to K-L score .....	75
<b>Table (9):</b>	Comparison between patients with K-L different grades and clinical parameters.....	78
<b>Table (10):</b>	Comparison between patients with K-L different grades as regards parametric clinical data.....	79
<b>Table (11):</b>	Correlation between BMP-2 and the studied parameters.....	81
<b>Table (12):</b>	Validity of BMP-2 in diagnosis of O.A .....	83

## List of Figures

<i>Figure No.</i>	<i>Title</i>	<i>Page No.</i>
-------------------	--------------	-----------------

F

# Introduction

**O**steoarthritis (O.A), also known as ‘osteoarthrosis’ is the most prevalent complex, degenerative chronic disease. It is a disorder of the hyaline joints characterized by wear, softening and thinning of the articular cartilage and diminished compliance of the sub-chondral bone (*Bijlsma et al., 2011*).

These pathological changes progressively lead to severe limitation of physical activity and great impairment of quality of life, which can ultimately lead to articular prosthetic substitution (*Loeser, 2010*).

O.A affects nearly half the elderly population worldwide. The patterns of O.A incidence and prevalence shows that it occurs in the hip, knee, foot, hand, wrist and spine and is rarely to occur in the ankle, elbow and shoulder (*Lories and Luyten, 2011*).

Many different factors contribute to the onset and progression of OA, these include genetics, age, sex, obesity and joint instability.

For the purpose of this thesis, these factors will be mentioned in brief, we will focus on the molecular pathways involved in cartilage and bone changes in OA. In particular, major factors involved such as bone morphogenetic proteins, will be discussed in details.

Multiple genetic factors can contribute to the incidence and severity of O.A and these may differ according to specific joint (hand, hip, knee, or spine), sex, and race. Generalized nodal O.A was twice as likely to occur in first degree relatives. Also, there is a significantly higher concordance for O.A between monozygotic twins than between dizygotic twins, and that the heritable component of O.A may be in the order of 50% to 65% (*Valdes et al., 2008*).

Several candidate genes encoding proteins of the extracellular matrix of the articular cartilage have been associated with early onset O.A. In addition to point mutations in type II collagen, inherited forms of O.A may be caused by mutations in several other genes that are expressed in cartilage, including those encoding types IV, V, and VI collagens, as well as cartilage oligomeric matrix protein (COMP). Other non structural proteins such as the secreted frizzled related protein 3 and von Willebrand factor genes have also been identified (*Miyamoto et al., 2008*).

Although older age is the greatest risk factor for O.A, O.A is not an inevitable consequence of growing old (*Shane Anderson and Loeser, 2010*). The mechanisms for the link between aging and O.A are incompletely understood. Cell stress and oxidative damage contribute to chronic inflammation that promotes age related diseases. This, results in senescence associated secretory phenotype, which has many of the characteristics of an osteoarthritic chondrocyte in terms of the cytokines, chemokines, and proteases produced (*Loeser, 2011*).

There is a marked increase in prevalence among women after the age of 40 years and the cause of this increase has been ascribed to estrogen insufficiency. Articular chondrocytes possess functional estrogen receptors, and there is evidence that estrogen can upregulate proteoglycan synthesis. In support of a role for estrogens in O.A, there are human studies indicating that estrogen replacement therapy reduces the incidence of O.A (*Sniekers et al., 2008*).

Obesity is another important risk factor for O.A. An increase in mechanical forces across weight-bearing joints is probably the primary factor leading to joint degeneration. The majority of obese patients exhibit varus knee deformities, which result in increased joint reactive forces in the medial compartment of the knee, thereby accelerating the degenerative process (*Anderson and Felson, 1988*).

Emerging data implicate a crucial role for adipocytes in regulation of cells present in bone, cartilage, and other tissues of the joint. Protein such as leptin may have important involvement in the onset and progression of O.A. In addition, adipocyte derived factors such as interleukin (IL)-6 and C reactive protein (CRP) appear to be procatabolic for chondrocytes (*Dumond et al., 2003*).

Whether joint malalignment leads to the development of O.A is a matter of debate. However, the evidence does indicate that varus or valgus deformities are associated with risk for progression of knee O.A (*Sharma, 2006*). As regards their mechanisms, altered joint geometry may interfere with nutrition of the cartilage, or it

may alter load distribution, either of which may result in altered biochemical composition of the cartilage (*Hunter et al., 2007*).

The first consideration with respect to exercise is whether wear and tear resulting from repetitive use of articular cartilage leads to progressive O.A. However, exercise in the absence of injury, has not been found to increase one's risk of developing O.A, on the contrary it helps O.A of the knee by strengthening the muscles surrounding the joint providing better support and also act as shock absorbers (*Bosomworth, 2009*).

In contrast with degradation occurring in O.A, a remodelling process is initiated as a response to injury, resulting in osteophytes at the joint margins. The bone morphogenic proteins (BMPs) are involved in protection against cartilage destruction and in new bone and cartilage formation. They stimulate production of extracellular matrix (ECM) components by chondrocytes and have the ability to counteract catabolic cytokines like interleukin 1 (IL-1) (*Matsubara et al., 2008*).

The bone morphogenic proteins are subset of the (TGF-  $\beta$ ) superfamily. Although other growth factors such as fibroblast growth factor (FGF) and platelet-derived growth factor (PDGF) can be found in bone and have various effects on bone and cartilage cells in vitro, only BMPs have been demonstrated to induce either cartilage or bone formation in vivo (*Issa et al., 2006*).

Bone morphogenic proteins are produced by mesenchymal cells, osteoblasts and chondrocytes. Different BMPs as-2,-4and-7 function independently or in collaboration with each other, as well as with other members of the TGF $\beta$  superfamily, to trigger a cascade of events that promote the formation of cartilage and bone. Cellular processes stimulated include chemotaxis, mesenchymal cell proliferation and differentiation, angiogenesis and synthesis of extracellular matrix (*Reddi et al., 2001*).

It has been proposed that BMP-2 may be one of the most potent inducers of mesenchymal cell differentiation to osteoblasts, while the remaining BMPs promote the maturation of committed osteoblasts (*Cheng et al., 2003*). Moreover, BMP-2 controls the expression of several other BMPs and when its activity is blocked, marrow stromal stem cells fail to differentiate into osteoblasts (*Edgar et al., 2007*).

Although BMP-2 is able to induce cartilage formation, it was found that its expression in healthy cartilage was low but that its expression was elevated in areas surrounding cartilage lesions and in OA cartilage. This could indicate that BMP-2 is upregulated as a reparative response but could also indicate that BMP-2 is merely upregulated as a pathological side effect, thereby further stimulating injury (*Dell'Accio., 2006*).